{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T22:18:53Z","timestamp":1768515533038,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.clinthera.2012.03.058","type":"journal-article","created":{"date-parts":[[2012,4,13]],"date-time":"2012-04-13T02:48:46Z","timestamp":1334285326000},"page":"1160-1169","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacokinetic and Pharmacodynamic Properties of the Calcimimetic Agent Cinacalcet (KRN1493) in Healthy Male Korean Subjects: A Randomized, Open-Label, Single Ascending\u2013Dose, Parallel-Group Study"],"prefix":"10.1016","volume":"34","clinical-trial-number":[{"clinical-trial-number":"nct00942773","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"SeungHwan","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namyi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-Hyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoung Soo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Goo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Sang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.03.058_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(09)60507-9","article-title":"Hyperparathyroidism","volume":"374","author":"Fraser","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2012.03.058_bib2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/sj.ki.5002287","article-title":"Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics","volume":"74","author":"Goodman","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2012.03.058_bib3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/MED.0b013e3283400945","article-title":"Renal bone disease","volume":"17","author":"Sprague","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"Suppl 5","key":"10.1016\/j.clinthera.2012.03.058_bib4","doi-asserted-by":"crossref","first-page":"V9","DOI":"10.1093\/ndt\/gfh1050","article-title":"Achieving therapeutic targets in the treatment of secondary hyperparathyroidism","volume":"19","author":"Cunningham","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2012.03.058_bib5","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1007\/s00467-003-1290-2","article-title":"Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials","volume":"18","author":"Goodman","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.clinthera.2012.03.058_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1152\/physrev.2001.81.1.239","article-title":"Extracellular calcium sensing and extracellular calcium signaling","volume":"81","author":"Brown","year":"2001","journal-title":"Physiol Rev"},{"key":"10.1016\/j.clinthera.2012.03.058_bib7","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1073\/pnas.95.7.4040","article-title":"Calcimimetics with potent and selective activity on the parathyroid calcium receptor","volume":"95","author":"Nemeth","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2012.03.058_bib8","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","article-title":"The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism","volume":"13","author":"Goodman","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2012.03.058_bib9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/01.ASN.0000050224.03126.AD","article-title":"The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease","volume":"14","author":"Quarles","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2012.03.058_bib10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.vph.2007.06.010","article-title":"Calcimimetic, AMG 073, induces relaxation on isolated rat aorta","volume":"47","author":"Smajilovic","year":"2007","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.clinthera.2012.03.058_bib11","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","article-title":"The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism","volume":"63","author":"Lindberg","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2012.03.058_bib12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2165\/00003088-200746060-00003","article-title":"Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole","volume":"46","author":"Harris","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2012.03.058_bib13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2165\/00044011-200828100-00004","article-title":"Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment: phase I, open-label, parallel-group, single-dose, single-centre study","volume":"28","author":"Padhi","year":"2008","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2012.03.058_bib14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/00003088-200544050-00004","article-title":"No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar\/Mimpara)","volume":"44","author":"Padhi","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2012.03.058_bib15","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.ajkd.2004.08.029","article-title":"Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily","volume":"44","author":"Harris","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2012.03.058_bib16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/00003495-200565020-00007","article-title":"Cinacalcet hydrochloride","volume":"65","author":"Barman Balfour","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2012.03.058_bib17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00003088-200948050-00002","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride","volume":"48","author":"Padhi","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2012.03.058_bib18","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1124\/dmd.104.000604","article-title":"Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models","volume":"32","author":"Kumar","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2012.03.058_bib19","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1517\/17425255.2011.585969","article-title":"Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs","volume":"7","author":"Sai","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2012.03.058_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2710.2011.01298.x","article-title":"Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations","author":"Yin","year":"2011","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.clinthera.2012.03.058_bib23","series-title":"Medical Neutrition Therapy","author":"Jang","year":"2011"},{"key":"10.1016\/j.clinthera.2012.03.058_bib24","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1177\/0091270007304103","article-title":"Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies","volume":"47","author":"Nakashima","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.03.058_bib25","series-title":"Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications","year":"2009"},{"key":"10.1016\/j.clinthera.2012.03.058_bib26","series-title":"Pharmacokinetic\u2013Pharmacodynamic Data Analysis: Concepts and Applications","first-page":"770","year":"1997"},{"key":"10.1016\/j.clinthera.2012.03.058_bib27","series-title":"Pharmacokinetics in Drug Development: Clinical Study Design and Analysis","year":"2004"},{"key":"10.1016\/j.clinthera.2012.03.058_bib28","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.03.058_bib29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/jcp.1030550306","article-title":"Ion association","volume":"55","author":"Walser","year":"1960","journal-title":"J Cell Comp Physiol"},{"key":"10.1016\/j.clinthera.2012.03.058_bib30","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/clinchem\/38.3.400","article-title":"Circadian changes in plasma phosphate concentration, urinary phosphate excretion, and cellular phosphate shifts","volume":"38","author":"Kemp","year":"1992","journal-title":"Clin Chem"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181200238X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181200238X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T20:10:58Z","timestamp":1642018258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929181200238X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S014929181200238X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.03.058","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}